Abstract
The development of inhibitors of tumor necrosis factor (TNF) evolved from a targeted bench-to-bedside approach in which lessons learned from basic pathophysiological research were tested in patients with debilitating chronic inflammatory diseases, particularly rheumatoid arthritis (RA) and inflammatory bowel disease. Insofar as all prior treatments for (RA) evolved primarily from serendipitous observations, the TNF inhibitors represent the first “rationally based” treatment, as well as the first Food and Drug Administration (FDA)-approved recombinant proteins (“biologies”) for the treatment of RA. This chapter will focus on RA as a paradigm for examining the role of TNF in the pathogenesis and propagation of chronic inflammation, and for evaluating anti-TNF therapy as a strategy for the treatment of chronic inflammatory disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
